News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MDFZF
Medifocus’ strategy to capitalize on the proprietary Prolieve Thermodilation
System is to generate recurring revenues through our mobile service and the sale of our disposable catheter kits.
#OTC #TSXV #equity
|
Followers
|
15
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
402
|
|
Created
|
08/01/11
|
Type
|
Free
|
| Moderators | |||
Our treatment is designed with patients' needs and comfort in mind.
Medifocus, Inc. https://medifocusinc.com/ (TSXV-MFS, OTC-MDFZF) TWITTER @medifocus1 develops and commercializes minimally invasive treatment systems used in treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia (“BPH”). The Company owns two technology platforms with approximately 100 issued and pending US and international patents:
1. The “Endo-thermotherapy Platform”, and
2. The “Adaptive Phased Array Microwave Focusing Platform”.
Based on these proprietary technology platforms, the Company has developed two advanced therapeutic products: the Adaptive Phased Array (APA)-1000 system for treatment of breast cancer and the Prolieve® system for the treatment of BPH. The APA-1000 uses precisely focused and controlled microwave energy to shrink breast cancer tumors without side-effects on the surrounding tissues to produce better treatment outcomes. The Company has received regulatory approvals to complete the APA 1000’s pivotal Phase-III clinical trials, the final step before marketing approval. The U.S. FDA-approved Prolieve® System is a medical device based on endo-thermotherapy that both heats the prostate and dilates the prostatic urethra. The Prolieve® System is a minimally invasive in-office treatment option for the symptoms of enlarged prostate in men. The Prolieve® System is a revenue generating product catering to the multi billion dollar BPH market. The Company is currently focusing on marketing Prolieve® for the treatment of BPH and accelerating the APA 1000 breast cancer system’s Phase III study.
Medifocus’ strategy to capitalize on the proprietary Prolieve Thermodilation System is to generate recurring revenues through our mobile service and the sale of our disposable catheter kits.
APA-1000
The Company’s long term goal is to deploy these technology platforms to improve outcomes and standards of care in cancerous and benign tumors treatment.
